Wiesbaden, Hesse, Germany
- Academic degree in veterinary medicine, doctoral degree in animal physiology - Over 20 years’ professional experience in the pharmaceutical industry Research and Development both for Human Pharma and Animal Health - Strong experience in Project and Portfolio Management as well as in Line Function leadership - Highly motivated leader of cross-functional and multi-national development teams for human prescription medicines and veterinary pharmaceuticals - In-depth knowledge of all aspects of drug development (non-clinical, clinical, CMC, Regulatory) - Hands on extensive experience with in-depth evaluations of in-licensing opportunities for pipeline products in human pharmaceuticals and animal health - Strong background as leader as well as sponsor for several strategic- and organizational development projects within Human Prescription Medicines and Animal Health
Central Drug Development Planning Function: Creation and maintenance of all plans for drug development projects at Boehringer Ingelheim, including clinical, non-clinical, and pharmaceutical work packages, from molecule selection to approval. This function not only facilitates efficient planning for the development of innovative therapies but also forms the basis for resource and budget management within the development organization. Science and Technology: Our focus on external medical-scientific and pharmaceutical-technical innovations ensures that innovative research results lead to faster and more efficient development of new drugs and therapies, making new medications and treatment options available to patients in a shorter timeframe. Patient-Centred Development: Patient-centered development ensures that medical needs, therapeutic gaps, and patient preferences are understood and placed at the centre of our innovative drug development. This is achieved through intensive discussions with patient groups and organizations. The insights gained are used to develop more personalized and effective treatment options that are optimally tailored to the specific needs of patients. Sustainability in drug development: The goal is to make clinical development, as well as the manufacture and distribution of pharmaceuticals, more sustainable and environmentally friendly. In addition to cost savings and efficient use of resources, this contributes to improved economic efficiency in drug development and reduced environmental impact from the production and disposal of medicines. Central function accountable for the Digitalization Strategy within Development CMC and interface function with the BI Computational Innovation Unit.
As Head Drug & Device CREA having full accountability for non-clinical deliverables for the therapeutic areas Mental Health and Eye Health at Boehringer Ingelheim. Providing leadership to a team of Drug & Device Leads steering key processes and workpackages in CMC development, non-clinical safety and DMPK for the development of innovative therapeutic solutions. Defining the strategies for performing non-clinical portfolio work competitively with the right mix of external and internal capabilities and capacities. Supporting the Global Development organization by planning, tracking and steering internal cpacities, budgets for outsourcing and capital investments. Monitoring of organizational performance for the Development organization using KPIs, realize process improvements through CPI/IT/strategic projects to realize an efficient and cost effective development of new drugs.
Leading a state of the art Global R&D Project Management organization accountable for steering key processes and workpackages in CMC development and non-clinical drug safety for development of innovative pharmaceuticals for humans. Defines the strategies for performing non-clinical portfolio work competitively with the right mix of external and internal capabilities and capacities. Supporting the Global Development organization by planning, tracking and steering budgets for outsourcing and capital investments. Monitoring of organizational performance for the Development organization using KPIs, realize process improvements through CPI/IT/strategic projects to realize an efficient and cost effective development of new drugs.
Leading the global organization for the clinical development of pharmaceutical therapeutics, parasiticides and biopharmaceuticals for prevention and treatment of diseases in companion animals and livestock. The clinical development organization consists > 100 scientists and technical staff at several sites in the US, Germany, France and Japan. In addition to this global function, I am responsible as Head R&D Operations Germany for the administrative oversight of the BI Animal Health R&D sites located in Germany (Ingelheim, Hannover, Rohrdorf) with approximately 250 employees.
Background: On January 1st 2017 Boehringer Ingelheim Animal Health formally closed the acquisition of Merial from Sanofi. With this acquisition the new BI Animal Health organization advanced to become the 2nd largest Animal Health Company in the world. As Global Integration Lead R&D I am leading an international and cross-functional team with the aim to integrate the heritage R&D organizations of Merial and BI Animal Health into a new best in the industry organization for research and development of innovative vaccines, pharmaceuticals and diagnostics for prevention and treatment of diseases in livestock and companion animals. The new BI Animal Health R&D organization consist of approximately 20 R&D sites with major footprints in the US, France, Germany, China, Brazil, Japan and Australia/NZ with ~ 1300 employees. Some of the main tasks the R&D Integration team is focusing on: - Design and implement overall R&D governance model including decision bodies and an efficient portfolio management system - Integrate the pipeline project portfolios of both legacy organizations and validate and prioritize them against the overall strategy - Ensure compliance during the integration process and thereafter - Define and implement an updated project management model - Define ambition for R&D culture and detail respective initiatives for implementation
Responsibilities: - Leading the global pharmaceutical R&D organization including pre-clinical and clinical sciences, CMC development, International Project Management, Neutraceutical Care R&D and Antiparasitics R&D consisting of groups in Europe, US, Japan, and India - As Species Portfolio Head R&D strategic responsibility for the Companion Animals and Equine pipeline portfolio jointly with the Species Portfolio Head Marketing - Assuring operational and strategic alignment between R&D sites, use of “best practices”, sharing of know-how and maximization of synergies within the Global R&D organization - Responsible for operational excellence through hiring and retaining high quality staff in pharmaceuticals R&D - Ensure that in-licensing opportunities are thoroughly evaluated and clear recommendations are provided to Business Development and the Global Management Team. - Chairman of the Pharmaceutical Research Review Committee with focus on research, innovation and the early pipeline projects